Loading organizations...
Key people at Covidien.
Orchestrated by Tyco International chief executive Ed Breen, Covidien was officially founded in June 2007 as an independent spin-off manufacturing global healthcare products and medical devices. The publicly traded corporation maintained its legal headquarters in Dublin, Ireland, and its primary operational headquarters in Mansfield, Massachusetts, while employing over 41,000 workers across 70 different countries. Serving hospitals, clinicians, and patients worldwide, the enterprise generated revenue by supplying a wide range of clinical equipment, including specialized mechanical ventilators. Under the strategic leadership of chief executives Richard Meelia and Jose Almeida, the business reached a peak annual revenue of 11 billion 600 million dollars during fiscal year 2011. Despite terminating a government ventilator contract in 2014 due to profitability concerns, the company emphasized healthcare innovation until Medtronic acquired it for 42 billion 900 million dollars in January 2015.
Covidien plc was an Irish-headquartered global healthcare products company specializing in the development, manufacture, and sale of medical devices, pharmaceuticals, and supplies for clinical and home settings.[1][2][7] Operating through three segments—Medical Devices (e.g., endomechanical instruments, vascular products, oximetry, ventilation), Pharmaceuticals (specialty drugs, contrast products), and Medical Supplies (nursing care, surgical products)—it served hospitals, healthcare providers, and patients worldwide, addressing needs in surgery, monitoring, wound care, and ventilation.[1][3] At its peak in 2011, Covidien employed over 41,000 people across 59 countries, with products sold in more than 140 nations, but it ceased independent operations after acquisition by Medtronic in 2015.[1][2][6]
Covidien traces its roots to 1903 when Henry P. Kendall acquired a textile mill in Walpole, Massachusetts, evolving it into Kendall Healthcare, a leader in surgical dressings and mesh products; over the century, it incorporated innovators like Davis & Geck (1909, surgical sutures), Nellcor Puritan Bennett (pulse oximetry via Mallinckrodt acquisition), and others in vascular and GI imaging.[3] In 1960, it became Tyco Healthcare under Tyco International, expanding through over 50 acquisitions from 1996-2002 under President Richard J. Meelia, broadening its portfolio across hospital settings.[1][4] Tyco spun off its healthcare division on June 29, 2007, forming Covidien plc in Dublin, Ireland (with operations in Mansfield, Massachusetts), led from 2011 by CEO Jose E. Almeida; this independence enabled focused global growth and R&D investment.[1][2][4]
Covidien rode the wave of medical device consolidation and innovation in minimally invasive surgery, patient monitoring, and critical care amid rising demand for advanced healthcare tech in aging populations and pandemics.[3] Its timing post-2007 spin-off capitalized on healthcare globalization and R&D needs, with acquisitions filling gaps in ventilation and wearables during a period of regulatory pushes for portable devices (e.g., U.S. government ventilator contracts).[2][5] Market forces like supply chain integration favored its scale, influencing the ecosystem through supply dominance but contributing to fragility—e.g., canceling a low-cost ventilator project in 2014 for profitability, delaying pandemic readiness, and enabling Medtronic's $42.9B acquisition for "synergies" that consolidated manufacturing.[2][5][6] This shaped medtech by prioritizing profitable scale over niche innovation, amplifying tax inversion trends.[5]
Covidien no longer exists independently, fully integrated into Medtronic since 2015, where its portfolio bolsters Medtronic's leadership in health tech innovation from pacemakers to ventilation.[2][6] Post-merger, trends like supply chain resilience, AI-driven monitoring, and pandemic preparedness will shape its legacy within Medtronic, potentially addressing past criticisms through diversified manufacturing and regulatory compliance. Its influence endures in consolidated medtech, driving efficiencies but underscoring risks of over-reliance on giants—echoing its origin as a spun-off innovator that redefined healthcare scale.[5][6]
Key people at Covidien.
